United Therapeutics (UTHR) Receiving Somewhat Positive Media Coverage, Analysis Finds
Headlines about United Therapeutics (NASDAQ:UTHR) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. United Therapeutics earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.5587111695739 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern’s analysis:
- BRIEF-Corsair Pharma And United Therapeutics Enter Into Strategic Collaboration To Advance Novel Treprostinil Prodrugs (UTHR) (markets.businessinsider.com)
- Corsair Pharma and United Therapeutics Enter into Strategic Collaboration to Advance Novel Treprostinil Prodrugs (finance.yahoo.com)
- Best Biotech Stock Trades and Mergers to Watch in 2018 – TheStreet.com (thestreet.com)
- Krensavage Asset Management Increased Its Holding in United Therapeutics (UTHR) by $8.60 Million as Market Value … – Hill Country Times (hillcountrytimes.com)
- Q2 2018 Earnings Forecast for United Therapeutics Co. Issued By Wedbush (UTHR) (americanbankingnews.com)
Several research analysts recently commented on UTHR shares. TheStreet raised United Therapeutics from a “c+” rating to a “b” rating in a research note on Friday, December 15th. ValuEngine raised United Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 30th. Oppenheimer reissued a “buy” rating on shares of United Therapeutics in a research note on Friday, September 8th. Cowen reissued a “hold” rating and set a $129.00 target price on shares of United Therapeutics in a research note on Friday, October 27th. Finally, HC Wainwright reissued a “hold” rating and set a $95.00 target price on shares of United Therapeutics in a research note on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $138.00.
United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.01 by $2.26. The business had revenue of $445.50 million during the quarter, compared to analysts’ expectations of $426.43 million. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.23 EPS. research analysts expect that United Therapeutics will post 12.96 earnings per share for the current fiscal year.
In other news, CEO Martine A. Rothblatt sold 1,263 shares of the company’s stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $120.20, for a total transaction of $151,812.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christopher Causey sold 580 shares of the company’s stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $122.00, for a total value of $70,760.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,872 shares of company stock valued at $2,302,672. Insiders own 7.80% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/01/03/united-therapeutics-uthr-receiving-somewhat-positive-media-coverage-analysis-finds.html.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.